Key Takeaways
- Oscar Health (OSCR) stock surged approximately 11% on Wednesday following CEO Mark Bertolini’s acquisition of 1 million shares at $11.92 apiece.
- The $11.92M deal was executed as a private placement rather than through open-market channels, with new shares issued directly to the executive.
- Bertolini’s holdings now total 10.2M shares, accounting for 10.87% of Oscar Health’s equity.
- The stock had previously gained roughly 7% on Tuesday after federal officials announced a 2.5% increase in Medicare Advantage payment rates for 2027.
- Despite recording $443.2M in net losses for 2025, Oscar is projecting 60% revenue expansion in 2026, with targets between $18.7B and $19B.
Oscar Health (OSCR) is currently trading at $14.43, reflecting a $2.21 increase (+15.29%) as of the opening bell.
Oscar Health CEO Mark Bertolini captured market attention this week with a significant stock purchase—acquiring 1 million shares at $11.92 per share, totaling $11.92M. This substantial investment in the health insurance provider sent shares climbing approximately 11% during Wednesday’s morning session.
Regulatory documents filed after Tuesday’s trading session revealed the transaction occurred on Monday, April 6. Bertolini, formerly at the helm of Aetna, structured the deal in a manner that differs from conventional insider purchases.
According to the SEC Form 4 filing, this transaction was classified as a private placement. Rather than purchasing existing shares on the open market, Oscar issued 1 million newly created shares directly to Bertolini at $11.92—matching the closing price used that day for tax withholding on vested performance shares.
This arrangement provided Oscar with $11.92M in new capital while expanding Bertolini’s position to 10,196,876 shares, or 10.87% of the company. The dilutive impact on existing shareholders remained relatively modest.
Financial Performance Analysis
Oscar’s 2025 results showcase a company experiencing rapid expansion while continuing to operate at a loss. Annual revenue reached $11.7B, representing substantial growth from the previous year’s $9.18B. The member base expanded to an all-time high of 3.4 million individuals. However, the company recorded net losses of $443.2M, alongside operating losses totaling $396.4M.
Looking ahead to 2026, management has set ambitious targets: revenue between $18.7B and $19B—representing approximately 60% year-over-year growth—with a medical-loss ratio projected at 82.4% to 83.4%. Wall Street analysts forecast earnings per share of $0.77 for 2026, potentially marking the company’s transition to profitability.
These are aggressive objectives. Bertolini’s substantial personal investment signals his confidence in achieving them.
For context, consider the industry landscape: UnitedHealth Group reported Q4 2025 revenue of $113.2B, up 12.3% from the prior year. Meanwhile, Centene and Molina Healthcare delivered single-digit growth percentages. Oscar’s expansion trajectory stands out significantly, even though profitability remains elusive.
Understanding the Transaction Type
It’s important to distinguish what this transaction represents. A conventional open-market insider purchase—where an executive buys shares at prevailing market prices, accepts potential slippage, and risks immediate paper losses—generally sends a stronger confidence signal. That type of purchase communicates: “I believe in this valuation today.”
A private placement operates differently. Bertolini didn’t execute a spontaneous market order. He acquired shares at a predetermined fair market value as part of a structured transaction linked to equity vesting. Oscar received capital; Bertolini expanded his ownership.
Nevertheless, Bertolini had the option to liquidate vested shares for tax obligations and pocket the proceeds. Instead, he opted to increase his stake. At today’s valuation, his Oscar holdings are worth approximately $125M.
The stock had already advanced roughly 7% on Tuesday following the federal government’s confirmation of a 2.5% Medicare Advantage reimbursement rate increase for 2027—exceeding the initial proposal that called for maintaining flat rates.
Oscar’s first quarter 2025 earnings release is scheduled for May 6 before market hours.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
